Growth-inhibitory activity of interferon-beta against human colorectal carcinoma cell lines

Int J Cancer. 1989 Mar 15;43(3):526-30. doi: 10.1002/ijc.2910430331.

Abstract

Recombinant human interferon beta (rIFN-beta) inhibited in a time- and dose-dependent manner the proliferation of 18/18 human colon carcinoma cell lines in monolayer culture and 8/9 lines in a soft agar assay but had no effect on 4 human fibroblast cell lines. Maximal inhibition of cell proliferation by rIFN-beta required repetitive treatment (every 2 days) with lymphokine (50 units/ml). Furthermore, the inhibitory activity of rIFN-beta was neutralized by polyclonal antibodies against natural IFN-beta. In contrast to rIFN-beta, rIFN-alpha was inactive against all colon cell lines tested, and rIFN-gamma, with the exception of HT-29 cells, was similarly ineffective. These data demonstrate that rIFN-beta is a potent growth inhibitor of colon carcinoma cells in vitro, and suggest that studies on its mechanism of action may lead to a better understanding of the regulation of colon tumor cell proliferation.

MeSH terms

  • Adenocarcinoma / therapy*
  • Colorectal Neoplasms / therapy*
  • Humans
  • Interferon Type I / pharmacology*
  • Interferon-gamma / pharmacology
  • Recombinant Proteins
  • Time Factors
  • Tumor Cells, Cultured

Substances

  • Interferon Type I
  • Recombinant Proteins
  • Interferon-gamma